Dersimelagon (MT-7117)

No product-specific budget impact model, cost-effectiveness analysis, or health technology assessment of dersimelagon exists, and no United States wholesale acquisition cost or average sales price has been announced. The United Kingdom horizon-scanning briefing recorded the cost as confidential. The Dutch horizon scan gives an expected cost of €71,000 per patient per year, which that source states is derived from the median cost of medicines in Anatomical Therapeutic Chemical class D02BB in the Netherlands rather than from a manufacturer price. The payer record for afamelanotide, the only approved therapy, is mixed: the National Institute for Health and Care Excellence did not recommend it, with evidence review group estimates from £133,748 to £1,958,162 per quality-adjusted life year gained at a stated implant cost of £13,209 excluding value added tax; Germany accepted an annual cost of €51,875.85 to €69,167.80; Norway declined funding; and the Netherlands and Scotland recommended access. Current treated prevalence is low, with 7.6% of claims-identified patients in the United States receiving any treatment and 3.9% receiving afamelanotide.